Citation Tools
PDFClinical/translational cancer immunotherapy
Original research
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma